/KRRO
KRRO Stock - Korro Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$7.88+0.77%
+$0.06 (+0.77%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.13
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.5
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+217.3%upside
Target: $25.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KRRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.80 – $7.96
TARGET (TP)$25.00
STOP LOSS$7.25
RISK/REWARD1:27.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.87
52W High$55.89
52W Low$5.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.27M | N/A | N/A | $14.07M | $36.98M |
| Gross Profit | $2.27M | N/A | N/A | $10.23M | $35.40M |
| Gross Margin | 100.0% | N/A | N/A | 72.7% | 95.7% |
| Operating Income | $-91,910,000 | $-84,534,000 | $-58,998,000 | $-84,031,000 | $-27,550,000 |
| Net Income | $-83,581,000 | $-81,172,000 | $-58,032,000 | $-84,686,000 | $-26,511,000 |
| Net Margin | -3680.4% | N/A | N/A | -602.0% | -71.7% |
| EPS | $-9.37 | $-53.09 | $-227.58 | $-4.94 | $-41.10 |
Company Overview
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
7
58%
Hold / Neutral
4
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
8 Bullish4 Neutral/Bearish
Price Targets
$92
Average Target
↑ 1069.5% Upside
Now
$7
Low
$92
Average
$180
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $8 |
| November 13th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| November 13th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| November 13th 2025 | Chardan Capital Markets | Downgrade | Neutral | $7 |
| November 13th 2025 | Raymond James | Downgrade | Market Perform | - |
| November 13th 2025 | William Blair | Downgrade | Market Perform | - |
| November 13th 2025 | Piper Sandler | Downgrade | Neutral | $11 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $74 |
| April 16th 2025 | Chardan Capital Markets | Initiation | Buy | $25 |
| January 10th 2025 | Oppenheimer | Initiation | Outperform | $155 |
| October 21st 2024 | Raymond James | Initiation | Strong Buy | $153 |
| August 14th 2024 | William Blair | Initiation | Outperform | $180 |
| March 28th 2024 | H.C. Wainwright | Reiterated | Buy | $115← $100 |
| February 27th 2024 | BMO Capital Markets | Initiation | Outperform | $120 |
| December 4th 2023 | H.C. Wainwright | Initiation | Buy | $100 |
Earnings History & Surprises
KRROBeat Rate
67%
Last 15 quarters
Avg Surprise
-50.9%
EPS vs Estimate
Beats / Misses
10/5
Last 12 quarters
Latest EPS
$-1.92
Q4 2025
EPS Surprise History
Q1 24
-986.9%
$-25.65vs$-2.36
Q2 24
-3.4%
$-2.44vs$-2.36
Q3 24
-1.3%
$-2.43vs$-2.40
Q4 24
+11.4%
$-2.26vs$-2.55
Q1 25
+3.0%
$-2.26vs$-2.33
Q2 25
+4.2%
$-2.49vs$-2.60
Q3 25
-7.9%
$-2.74vs$-2.54
Q4 25
+26.4%
$-1.92vs$-2.61
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-1.86 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-2.61 | $-1.92 | +26.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-2.54 | $-2.74 | -7.9% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-2.60 | $-2.49 | +4.2% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-2.33 | $-2.26 | +3.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-2.55 | $-2.26 | +11.4% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-2.40 | $-2.43 | -1.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-2.36 | $-2.44 | -3.4% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-2.36 | $-25.65 | -986.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-17.73 | $-15.50 | +12.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.44 | $-0.30 | +31.8% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.39 | $-0.55 | -41.0% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | $-31.55 | $-3.21 | +89.8% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-28.50 | $-3.74 | +86.9% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-33.17 | $-30.43 | +8.3% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-33.59 | — | — |
Q4 2021 | Dec 30, 2021 | $-31.80 | $-31.07 | +2.3% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | — | $-36.51 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-25.78 | — | — |
Latest News
Jones Trading Downgrades Korro Bio to Hold
📉 NegativeBenzinga•Nov 14, 2025, 12:16 PM
William Blair Downgrades Korro Bio to Market Perform
📉 NegativeBenzinga•Nov 13, 2025, 08:48 PM
RBC Capital Downgrades Korro Bio to Sector Perform, Lowers Price Target to $8
📉 NegativeBenzinga•Nov 13, 2025, 05:20 PM
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial
📉 NegativeSeeking Alpha•Nov 13, 2025, 02:49 PM
Korro Bio shares are trading lower after the company reported Q3 financial results, agreed to wind-down its research and development activities after Novo Nordisk paused its agreement for 12 month. Also, multiple firms downgraded the stock.
📉 NegativeBenzinga•Nov 13, 2025, 02:05 PM•Also:
Cantor Fitzgerald Downgrades Korro Bio to Neutral
📉 NegativeBenzinga•Nov 13, 2025, 01:28 PM
Chardan Capital Downgrades Korro Bio to Neutral, Lowers Price Target to $7
📉 NegativeBenzinga•Nov 13, 2025, 12:56 PM
HC Wainwright & Co. Downgrades Korro Bio to Neutral
➖ NeutralBenzinga•Nov 13, 2025, 12:39 PM
Korro Bio Says Effective Nov 11, Co & Novo Nordisk Amend Collaboration Agreement; Co & Novo Nordisk Pause Agreement For 12 Months; Agreed To Wind-Down Its Research And Development Activities In Connection With The License Agreement
📉 NegativeBenzinga•Nov 12, 2025, 10:25 PM•Also:
Korro Bio Shares Resume Trade
➖ NeutralBenzinga•Nov 12, 2025, 09:51 PM
Korro Bio Announces 34% Workforce Reduction To Extend Cash Runway Into Second Half Of 2027 To Provide Sufficient Capital To Deliver Clinical Data From KRRO-121; Estimates That It Will Incur One-time Restructuring Charges Of ~$2.4M
📉 NegativeBenzinga•Nov 12, 2025, 09:51 PM
Korro Bio Q3 EPS $(1.92) Beats $(2.59) Estimate, Sales $1.090M Beat $578.222K Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:46 PM
Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 12, 2025, 09:30 PM
Korro To Reduce Work Force By About A Third, Will Pivot To GalNAc
📉 NegativeBenzinga•Nov 12, 2025, 09:29 PM
Korro Announces KRRO-110 Did Not Reach Projected Levels Of Functional Protein Following A Single Administration
📉 NegativeBenzinga•Nov 12, 2025, 09:20 PM
Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 12, 2025, 09:01 PM
Korro Bio shares are trading higher. Clear Street initiated coverage on the stock with a Buy rating and price target of $93.
📈 PositiveBenzinga•Oct 31, 2025, 07:03 PM
Clear Street Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $93
📈 PositiveBenzinga•Oct 31, 2025, 09:45 AM
Korro Bio CFO Vineet Agarwal To Resign, Effective Oct. 17; Ram Aiyar Named Interim Successor
➖ NeutralBenzinga•Oct 8, 2025, 11:37 AM
Frequently Asked Questions about KRRO
What is KRRO's current stock price?
Korro Bio, Inc. (KRRO) is currently trading at $7.88 per share. The stock has moved +0.77% today.
What is the analyst price target for KRRO?
The average analyst price target for KRRO is $25.00, based on 1 analyst.
What sector is Korro Bio, Inc. in?
Korro Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KRRO's market cap?
Korro Bio, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does KRRO pay dividends?
No, Korro Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to KRRO for comparison